Based on the above-mentioned clinical evidence, which mainly refer to HCC of any etiology and not specifically to NAFLD-associated HCC, TNF-α may not be a suitable circulating biomarker for the early detection of HCC in cirrhotic patients, since its serum concentrations did not differ between cirrhotic patients with and without HCC. Here, TNF is linked to metabolic dysfunction-associated steatotic liver disease.